Safety Study of Repeat Doses of SUSTOL in Adults

Overview

This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).

Full Title of Study: “A Phase 4, Open-Label Safety Study of Repeat Doses of SUSTOL in Adult Subjects Receiving Chemotherapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2025

Interventions

  • Drug: SUSTOL
    • SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.

Arms, Groups and Cohorts

  • Experimental: Treatment Group

Clinical Trial Outcome Measures

Primary Measures

  • Number of subjects with potential impact of subject-reported ISRs on ADL in adult subjects with cancer administered SUSTOL.
    • Time Frame: 14 days

Participating in This Clinical Trial

Inclusion Criteria

1. Has cancer and is scheduled to receive MEC or AC regimen for at least 4 cycles of chemotherapy, and is prescribed SUSTOL for CINV prevention. 2. Has an Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Has life expectancy of greater than 6 months. 4. Able to receive standardized doses of dexamethasone for the prevention of emesis. 5. Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study. Exclusion Criteria:

1. Has hypersensitivity to granisetron, any component of SUSTOL, or any other 5-HT3 Receptor Antagonists. 2. Severe renal impairment (creatinine clearance [CLcr] <30 mL/min). 3. Symptomatic primary or metastatic central nervous system (CNS) disease. 4. Has participated in an interventional clinical study within 30 days of Cycle 1 Day 1. 5. Investigator assessment that subject would not be a good fit for the trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Heron Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.